Antidepressant effect in older depressed ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
Antidepressant effect in older depressed patients: the lessons of two agomelatine trials
Auteur(s) :
Goodwin, Guy M. [Auteur]
Thomas, Pierre [Auteur]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193
Heun, Reinhard [Auteur]
Boyer, Patrice [Auteur]
Picarel-Blanchot, Françoise [Auteur]
de Bodinat, Christian [Auteur]
Thomas, Pierre [Auteur]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193
Heun, Reinhard [Auteur]
Boyer, Patrice [Auteur]
Picarel-Blanchot, Françoise [Auteur]
de Bodinat, Christian [Auteur]
Titre de la revue :
International Clinical Psychopharmacology
Nom court de la revue :
Int Clin Psychopharmacol
Numéro :
32
Pagination :
184-194
Date de publication :
2017-07
ISSN :
1473-5857
Discipline(s) HAL :
Sciences cognitives
Résumé en anglais : [en]
The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly ...
Lire la suite >The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly in relation to patient selection, design and accuracy of diagnosis of depression) introduced in study 2 have improved the quality of recruitment of patients and the assay sensitivity. Study 1 lacked assay sensitivity, and among the many differences with study 2, the inclusion of unexpected mildly ill patients could have inflated the placebo response. The increased demands on investigators in study 2 appear to have reduced the placebo effect and showed a robust benefit of agomelatine. The two agomelatine studies offer the opportunity to discuss hypotheses that have been raised to explain the low level of response of older patients to available antidepressants.Lire moins >
Lire la suite >The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly in relation to patient selection, design and accuracy of diagnosis of depression) introduced in study 2 have improved the quality of recruitment of patients and the assay sensitivity. Study 1 lacked assay sensitivity, and among the many differences with study 2, the inclusion of unexpected mildly ill patients could have inflated the placebo response. The increased demands on investigators in study 2 appear to have reduced the placebo effect and showed a robust benefit of agomelatine. The two agomelatine studies offer the opportunity to discuss hypotheses that have been raised to explain the low level of response of older patients to available antidepressants.Lire moins >
Langue :
Anglais
Audience :
Non spécifiée
Établissement(s) :
Université de Lille
CNRS
CHU Lille
CNRS
CHU Lille
Équipe(s) de recherche :
Équipe Psychiatrie & Croyance (PsyCHIC)
Date de dépôt :
2019-02-13T14:21:40Z
2019-11-06T11:47:02Z
2019-11-06T11:47:02Z